We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 06, 2014

Limited HER2 Discordance in Metastatic Breast Cancer Treated With Trastuzumab

European Journal of Cancer


Additional Info

European Journal of Cancer
Limited Human Epidermal Growth Factor Receptor 2 Discordance in Metastatic Breast Cancer Patients Treated With Trastuzumab, A Population Based Study
Eur. J. Cancer 2014 Jan 31;[EPub Ahead of Print], JM van Rooijen, L de Munck, JC de Graaf, S Siesling, EG de Vries, JE Boers

Further Reading